The round was led by Khosla Ventures and Think.Health. The funds will support regulatory filing and early commercialization of the company's lead product, the TriVerity™ Acute Infection and Sepsis Test (TriVerity).

In addition to the leading investors Khosla Ventures and Think.Health, the Inflammatix Series E funding round included participation from Northpond Ventures, D1 Capital Partners, Iberis Capital, Vesalius BioCapital, OSF Healthcare, RAW Ventures, and others. The funding round brings Inflammatix's total private capital raised to more than $200 million, in addition to more than $50 million in grants and contracts from various government agencies and foundations.

Inflammatix, a pioneering molecular diagnostics company headquartered in Sunnyvale, California, USA, is developing novel diagnostics that rapidly read a patient's immune system to improve patient care and reduce major public health burdens. The Inflammatix tests will be developed to run on the company's sample-to-answer isothermal instrument platform, enabling the power of precision medicine at the point of care.